Generic Oxycontin is going off the market.
It looks like this may be the case.
Endo Pharmaceuticals challenged three of Purdue's patents on Oxycontin before they were set to expire. An initial court ruling was that the patents weren't enforceable...opening the door for generics to start entering the market in 2004.
But Purdue appealed soon after. This time it was ruled that Purdue's patents are valid, and that Endo's extended-release oxycodone products infringe the patents.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote